Nvidia(US:NVDA) Thenewswire·2025-10-29 16:45Core Viewpoint - Helix BioPharma Corp. reported a net loss of $5,205,000 for the fiscal year ended July 31, 2025, showing an improvement from a loss of $9,264,000 in the previous year, indicating progress in financial management and operational focus [2][13]. Financial Performance - The total comprehensive loss for the year was $5,205,000, translating to a loss of $0.09 per common share, compared to a loss of $0.21 per common share in the previous year [2][13]. - Research and Development expenses decreased by 40% to $3,558,000 from $5,977,000 in the previous year, attributed to the conclusion of a Phase Ib/II study and changes in stock-based compensation [8][9]. - Operating, general, and administration expenses also saw a significant reduction of 43%, totaling $1,839,000 compared to $3,262,000 in the prior year, primarily due to changes in service providers [10][11]. Clinical Development - The Phase Ib/II trial (LDOS006) for metastatic pancreatic adenocarcinoma was completed in October 2024, with ongoing data analysis and a Clinical Study Report expected in fall 2025 [3]. - A new Phase Ib/Randomized Phase II study (LDOS007) is in planning to assess L-DOS47 in combination with pembrolizumab for NSCLC, with positive feedback received from the FDA regarding the study design [4][6]. Corporate Development - The company decided to focus on developing L-DOS47 as a combination therapy for NSCLC, terminating collaborations with external research institutions that did not align with this focus [6]. - The company closed its laboratory in Edmonton, Canada, on October 31, 2024, and liquidated laboratory equipment while securing important documents and samples [6]. Capital and Liquidity - As of July 31, 2025, the company reported a working capital deficiency of $2,807,000 and an accumulated deficit of $215,876,000, indicating challenges in liquidity [13][18]. - The company closed a non-brokered private placement of 2,222,333 common shares at $0.75 per share, raising gross proceeds of $1,667,000 [7]. Research & Development Focus - The company’s pipeline includes L-DOS47, which targets CEACAM6-expressing tumors, and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at addressing significant unmet medical needs in oncology [20].